Clinically Important Decrease in Liver Stiffness Following Treatment for Hepatitis C: Outcome of the TraP HepC Nationwide Elimination Program [0.03%]
丙型肝炎治疗后临床意义重大的肝脏硬度降低：TraP HepC国家消除计划的结果
Smári Freyr Kristjánsson,Sigurdur Olafsson,Magnús Gottfredsson et al.
Smári Freyr Kristjánsson et al.
Background/Objectives: Direct-acting antiviral (DAA) therapy has been highly successful in treating chronic hepatitis C (CHC). The nationwide Treatment as Prevention of Hepatitis C (TraP HepC) initiative that was launched in Iceland in 2016...
Application of Biomaterials in the Development of Enteric-Coated Luminar Capsule Microneedles for Selective Delivery of Sofosbuvir to the Liver: A Promising Treatment for Hepatitis C [0.03%]
用于开发针对肝脏的选择性递送索夫布韦的肠溶透皮微针胶囊的生物材料在治疗丙型肝炎中的应用研究
Musyfira Sahra,Nurul Fitrayani,Abigael Alik Samma et al.
Musyfira Sahra et al.
In commercial applications, sofosbuvir (SOF) for hepatitis C is only available in tablet dosage form, resulting in minimal SOF accumulation in the liver (26.94%) due to its low intestinal permeability and high molecular weight (529.5 Da). T...
Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States [0.03%]
美国简化丙型肝炎病毒检测、监测和治疗的新方案的成本效益分析
Douglas Dietrich,Nancy Reau,Aijaz Ahmed et al.
Douglas Dietrich et al.
The hepatitis C virus (HCV) testing and treatment pathway in the United States (US) includes a range of tests and appointments causing delays and loss to follow-up. We assessed the cost-effectiveness of simplifying the pathway using an econ...
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment [0.03%]
日本丙型肝炎感染患者和医生的治疗偏好：一次独立选择实验
Daisuke Nakamoto,Yi Piao,Hajime Mizutani et al.
Daisuke Nakamoto et al.
Aims: This study was performed to evaluate patients' and physicians' preferences regarding hepatitis C virus (HCV) treatment in Japan, particularly focusing on direct-acting antivirals. Understanding these preferences is ...
Elucidating the multi-target pharmacological mechanism of Xiaoyandina for the treatment of hepatitis C virus based on bioinformatics and cyberpharmacology studies [0.03%]
基于生物信息学和网络药理学研究澄清小叶丹娜治疗丙型肝炎病毒的多靶点药理机制
Dilihuma Dilimulati,Nuerbiye Nueraihemaiti,Sendaer Hailati et al.
Dilihuma Dilimulati et al.
An estimated 170 million people worldwide suffer from chronic hepatitis C virus (HCV) infection, which is the main reason for liver transplantation in numerous nations. Traditional Chinese medicine is also frequently employed in medicine to...
Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma [0.03%]
直接抗病毒药物根除病毒对治愈丙型肝炎病毒相关肝细胞癌后临床结果的影响
Yuko Nagaoki,Kenji Yamaoka,Yasutoshi Fujii et al.
Yuko Nagaoki et al.
Background: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving survival rates....
Prophylactic Treatment of Hepatitis C Virus Infection After Kidney Transplantation with the Combination of Glecaprevir/Pibrentasvir and Sofosbuvir in a Highly Sensitized Hepatitis C Virus-Negative Recipient: A Case Report and Review of the Literature [0.03%]
肾移植后使用格卡瑞韦/皮布定韦和索非布韦联合治疗预防丙型肝炎病毒感染：病例报告及文献回顾（针对高致敏的丙型肝炎病毒阴性受者的治疗）
Tanja Belčič Mikič,Igor Sterle,Mojca Matičič et al.
Tanja Belčič Mikič et al.
Background: Since the discovery of successful direct-acting antiviral (DAA) treatment, kidneys from hepatitis C virus (HCV) RNA-positive donors represent a new opportunity to expand the organ donor pool for HCV-negative recipients. Case pre...
Case Reports
Biomedicines. 2025 Feb 14;13(2):472. DOI:10.3390/biomedicines13020472 2025
Improvement in anxiety symptoms during treatment of Hepatitis C in people who inject drugs: The HERO study [0.03%]
治疗注射毒品者的丙型肝炎过程中焦虑症状的改善： HERO研究
Jessica Obeysekare,Irene Pericot-Valverde,Snehal Lopes et al.
Jessica Obeysekare et al.
Background: Anxiety disorders frequently occur in people who inject drugs (PWID). This study aimed to explore changes in anxiety among PWID during and after treatment of hepatitis C virus (HCV) with direct-acting antivira...
Clinical and In vitro Data Shed New Light on the Therapeutic Advantages of Black Seeds (Nigella sativa) for the Treatment of Hepatitis C and Hepatitis B Viral Infections [0.03%]
临床和体外数据揭示黑种草（Nigella sativa）治疗丙型肝炎和乙型肝炎病毒的优势新信息
Naina Mohamed Pakkir Maideen,Rajkapoor Balasubramanian,Kumar Balasubramanian et al.
Naina Mohamed Pakkir Maideen et al.
Background: Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) can cause acute and chronic viral infections. Due to their higher costs, potential side effects and drug interactions, and associated risks, some patients wi...
Liver fibrosis regression in people living with HIV after successful treatment for hepatitis C [0.03%]
成功治疗丙型肝炎后HIV感染者的肝脏纤维化逆转
Jim Young,Shouao Wang,Rachel Sacks-Davis et al.
Jim Young et al.
Background: Successful treatment of hepatitis C virus (HCV) can lead to liver fibrosis regression. It is not known who will experience fibrosis regression or how quickly it will occur. ...
耗时 0.18436 秒，为您在
48229835
条记录里面共找到 1421 篇文章 [XML]